Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +351.03% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +351.03% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -109.56% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +3.74% | +2.90% | +2.49% | +22.35% | +27.67% |
| Weighted Average Shares Diluted Growth | +3.74% | +2.90% | +2.49% | +22.35% | +27.67% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +127.27% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -41.51% | -28.41% | -13.35% | -6.91% | +17.05% |
| Book Value per Share Growth | -38.61% | -23.81% | -13.66% | -20.25% | -8.87% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -86.03% | +133.33% | -18.18% | -46.67% | +329.63% |
| SG&A Expenses Growth | -41.76% | -36.68% | -4.57% | +33.62% | +23.53% |